U.S. Infectious Disease Diagnostics Markets - Biologics Market Research

U.S. Infectious Disease Diagnostics Markets

Published Date: April 2006
Published By: Frost & Sullivan
Order Code: R1-4808
Price: $6000 Electronic Access - Single User
$7500 Electronic Delivery - Global License
$6500 Hard Copy Mail Delivery

DESCRIPTION
Research Overview
This Frost & Sullivan research service, titled U.S. Infectious Disease Diagnostics Markets, provides comprehensive analysis of market drivers, restraints, challenges, and trends. Moreover, analysis of market share, competitive structure, revenue forecasts, and products is included. In this research, Frost & Sullivan's expert analysts thoroughly examine the following markets: molecular infectious disease diagnostics, immunoassay infectious disease diagnostics, and culture infectious disease diagnostics.
This analysis is available through our Clinical Diagnostics Growth Partnership Services program. With this program, clients receive industry-leading market research such as this, along with technical and econometric data and many interactive features including Analyst Inquiry Time and Client Councils. For more information on this custom subscription service, please click here.
Market Sectors
Frost & Sullivan's expert analysts thoroughly examine the following market sectors in this research:
Molecular
Immunoassay
Culture
Technologies
The following technologies are covered in this research:
PCR
Automated antimicrobial susceptibility testing
Molecular technologies and assays
Immunoassays
Microbiology culture methods
Market Overview
The U.S. infectious disease diagnostics market will play a significant role in the dynamic IVD market. This market is segmented according to molecular, immunoassays, and culture infectious disease products. Total market revenues for base year 2005 are $3,823.1 with a CAGR of 7.7%. The most substantial growth is expected in the molecular segment. The U.S. infectious disease diagnostics market is highly competitive and saturated
Tremendous growth opportunities exist in the U.S. infectious disease in-vitro diagnostics market. High growth areas include viral load testing, nosocomial infection screening, rapid influenza detection, and STD testing.
Rapid detection and fast turn-around time (TAT) are able to lower total overall healthcare costs. Quick TAT is especially relevant to infectious disease testing, as fast diagnosis increases treatment options and patient prognosis.
Technical superiority of molecular methods is phasing out other types or more traditional methods, such as culture based tests, which have TATs of only days and are labor intensive.